Skip to Main Content
Biological & Biomedical Sciences
Yale Home

INFORMATION FOR

    Headaches, Phase III

    A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

    What is the purpose of this trial?

    The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.

    • Trial with
      Eli Lilly and Company
    • Ages
      6 years - 17 years
    • Gender
      Both
    Find out more about who can participate in this trial

    Contact Information

    For more information about this study, including how to volunteer, contact Erin Weidman

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

    Create a volunteer profile

    Principal Investigator

    • Last Updated
      12/24/2024
    • Study HIC
      #2000028716

    Contact Information

    For more information about this study, including how to volunteer, contact Erin Weidman